Weight change at 68 weeks
In adults with overweight or obesity without diabetes, subcutaneous semaglutide (the weight-management form) plus lifestyle intervention produced significantly greater weight loss than placebo (mean -14.9% vs -2.4% body weight at 68 weeks in the trial's primary analysis population; reported elsewhere as approximately a -10.1 percentage-point placebo-subtracted difference across analyses).
- Study type
- Human trial
- Population
- 1,961 adults, BMI 30 or above (or 27 or above with 1 or more weight-related comorbidity), without diabetes; 68-week, phase 3, double-blind, placebo-controlled, multicentre (STEP 1).
- Source
- 1 Wilding et al., 2021
Limitation: Sponsor-funded (Novo Nordisk); efficacy shown for the injectable weight-management form specifically, not automatically generalisable to the oral tablet; STEP 1 extension data show substantial weight regain after treatment withdrawal.